Asia Pacific Small Molecule Drug Discovery Market

Market Introduction

Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and cost affectivity. The discovery of novel small molecule entities that are capable of specific interactions represents a significant challenge in the early stages of drug discovery.

Market Overview and Dynamics

The Asia Pacific small molecule drug discovery market is to reach US$ 8,797.47 million by 2027 from US$ 4,146.40 million in 2019. The market is anticipated to grow at a CAGR of 10.1% during 2019–2027. Factors such as increasing approval of small molecule drugs, growing demand for R&D from contract organizations, and rising adoption of small molecules in chronic disease treatments are expected to boost the growth of the small molecule drug discovery market. However, the market is likely to get impacted by the risk factor such as high drug development cost during the forecast period.

Key Market Segments

In terms of therapeutic area, the oncology cells segment accounted for the largest share of the Asia Pacific small molecule drug discovery market in 2019. lead generation and refinement segment accounted for the largest share of the Asia Pacific small molecule drug discovery market, by process/phase, in 2019.

Major Sources and Companies Listed

Several major primary and secondary sources associated with the Asia Pacific small molecule drug discovery market report are the World Health Organization (WHO), Centre for the Study of Drug Development (CSDD), and others.

Reasons to buy report

• It provides understanding of the Asia Pacific, small molecule drug discovery market landscape and identifies small molecule drug discovery market segments that are most likely to guarantee a strong return.
• It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific small molecule drug discovery market.
• It helps efficiently plan merger and acquisition, and partnership deals in the small molecule drug discovery market by identifying market segments with the most promising probable sales
• It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of small molecule drug discovery market performance of various segments pertaining to the Asia Pacific small molecule drug discovery market.
• It provides small molecule drug discovery market revenue forecast of the market based on various segments for the period from 2019 to 2027.

ASIA PACIFIC SMALL MOLECULE DRUG DISCOVERY MARKET SEGMENTATION

By Therapeutic Area

• Oncology
• Central Nervous System
• Cardiovascular
• Respiratory
• Orthopedics
• Immunology
• Rare Diseases
• Other Therapeutic Areas

By Process/Phase

• Target Discovery
• Target Validation
• Lead Generation and Refinement
• Preclinical Development

By Country

• Japan
• China
• India
• South Korea
• Australia

Company Profiles

• Pfizer Inc
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc
• Gilead Sciences, Inc
• Teva Pharmaceutical Industries Ltd

Asia Pacific Small Molecule Drug Discovery Market Strategic Insights

Asia Pacific Small Molecule Drug Discovery Market Segmentation Analysis

Asia Pacific Small Molecule Drug Discovery Market Report Highlights

Asia Pacific Small Molecule Drug Discovery Report Scope

Asia Pacific Small Molecule Drug Discovery Market Country and Regional Insights